Published online before print September 17, 2007, doi: 10.1161/HYPERTENSIONAHA.107.098350
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Hypertension. 2007;50:e163.)
© 2007 American Heart Association, Inc.
Letters to the Editor |
Do Commercially Available Assay Kits for B-Type Natriuretic Peptide Measure Pro-BNP1-108, as Well as BNP1-32?
Department of Hypertension and Cardiorenal Medicine, Dokkyo Medical University, Tochigi, Japan
Department of Pharmacology, National Cardiovascular Center, Research Institute, Osaka, Japan
Diagnostics Department, Shionogi & Co, Ltd, Osaka, Japan
Department of Hypertension and Cardiorenal Medicine, Dokkyo Medical University, Tochigi, Japan
We read with great interest the recent article by Heublein et al1 on plasma pro-BNP1-108 measurement with commercially available assay kits and the effect of pro-BNP1-108 on cGMP levels. They demonstrated that Shionogi’s or Biosite’s triage assay kit did not cross-react with pro-BNP1-108 and that pro-BNP1-108 did not increase intracellular cGMP levels in cardiac myocytes or fibroblasts.
Shionogi’s immunoradiometric assay kit uses 2 monoclonal antibodies: one recognizes the ring portion and the other recognizes the C-terminal tail. Therefore, this assay kit measures B-type natriuretic peptide independent of the length of the N-terminal extension from the ring structure. Indeed, Heublein et al1 reported that this assay kit measured BNP3-32, BNP5-32, and BNP1-32, but it did not measure C-terminal deletion forms of B-type natriuretic peptide, such as BNP1-30 and BNP1-28.2 Namely, this assay kit does not measure B-type natriuretic peptide lacking the ring portion or C-terminal tail. Thus, an N-terminal peptide pro-BNP1-76 lacking the ring portion cannot be recognized by the Shionogi’s immunoradiometric assay kit as shown in this article, whereas pro-BNP1-108 is detected by this kit with slight less affinity (
70% to 80%) than BNP1-32 (unpublished data). In fact, using Shionogi’s immunoradiometric assay kit, we detected and measured immunoreactivity corresponding with pro-BNP1-108, as well as BNP1-32, after gel filtration of human plasma.2
In the study by Heublein et al,1 moreover, pro-BNP1-108 did not increase intracellular cGMP levels in myocytes or fibroblasts. As for the activity of the natriuretic peptide, the studies of the structure-activity relationship demonstrated that the ring structure and the C-terminal tail are essential for eliciting the biological activity, whereas the N-terminal extension from the ring structure confirmed to be not essential.3,4 Indeed, Kangawa et al5 demonstrated previously that pro-atrial natriuretic peptide induced diuresis, natriuresis, and potassium excretion in the rat, although it was less potent than ANP1-28. BNP1-32 and pro-BNP1-108 act on the same natriuretic peptide receptor-A.
Taken together, available evidence suggests that Shionogi’s immunoradiometric assay kit measures pro-BNP1-108, as well as BNP1-32, and both of them are deduced to have the cGMP elevating activity. We do not know the reason why pro-BNP1-108 was not measured by Shionogi’s immunoradiometric assay kit or why pro-BNP did not increase the intracellular cGMP levels of cardiac myocytes and fibroblasts in the study by Heublein et al.1 It is reasonable to consider that the same reason diminished the antigenicity, as well as the biological activity, of the pro-BNP1-108 used in their experiment, although they did not precisely describe how they confirmed the structure of the recombinant pro-BNP1-108.
We agree with the notion by Heublein et al1 that clarifying the molecular form of BNP in plasma and its physiological action in heart failure are of importance. We believe that a better understanding of the structure, biological activity, and plasma concentrations of endogenously present natriuretic peptides, especially BNP, provides useful information in clinical medicine.
 |
Acknowledgments |
|---|
Sources of Funding
This work was supported in part by Scientific Research Grants-in-Aid 14570692 and 18590787 from the Ministry of Education, Culture, Sports, Science and Technology; by the Science Research Promotion Fund from the Promotion and Mutual Aid Corporation for Private Schools of Japan; by the Research Grant for Cardiovascular Diseases 17A-1 and 19C-7 from the Ministry of Health, Labor and Welfare; and by the Seki Minato Prize.
Disclosures
None.
|
References |
|---|
 Top References |
|---|
1. Heublein DM, Huntley BK, Boerrigter G, Cataliotti A, Sandberg SM, Redfield MM, Burnett JC Jr. Immunoreactivity and guanosine 3', 5'-cyclic monophosphate activating actions of various molecular forms of human B-type natriuretic peptide. Hypertension. 2007; 49: 1114–1119.
2. Shimizu H, Masuta K, Aono K, Asada H, Sasakura K, Tamaki M, Sugita K, Yamada K. Molecular forms of human brain natriuretic peptide in plasma. Clin Chim Acta. 2002; 316: 129–135.[CrossRef][Medline] [Order article via Infotrieve]
3. Garcia R, Thibault G, Seidah NG, Lazure C, Cantin M, Genest J, Chretien M. Structure-activity relationships of atrial natriuretic factor (ANF). II. Effect of chain-length modifications on vascular reactivity. Biochem Biophys Res Commun. 1985; 126: 178–184.[CrossRef][Medline] [Order article via Infotrieve]
4. De Lean A, Thibault G, Seidah NG, Lazure C, Gutkowska J, Chretien M, Genest J, Cantin M. Structure-activity relationships of atrial natriuretic factor (ANF). III. Correlation of receptor affinity with relative potency on aldosterone production in zona glomerulosa cells. Biochem Biophys Res Commun. 1985; 132: 360–367.[CrossRef][Medline] [Order article via Infotrieve]
5. Kangawa K, Fukuda A, Matsuo H. Structural identification of beta- and gamma-human atrial natriuretic polypeptides. Nature. 1985; 313: 397–400.[CrossRef][Medline] [Order article via Infotrieve]
This article has been cited by other articles:
 |
|
 |
|
  D. Heublein, B. Huntley, G. Boerrigter, A. Cataliotti, S. Sandberg, M. Redfield, and J. C. Burnett Jr Response to Do Commercially Available Assay Kits for B-Type Natriuretic Peptide Measure Pro-BNP1-108, as Well as BNP1-32? Hypertension, November 1, 2007; 50(5): e164 - e164. [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||